Back to News
Market Impact: 0.15
T·Time Launches Cash-Pay Compounded GLP-1 and GIP Injections With Flat Pricing
Source: GlobeNewswire
Healthcare & BiotechProduct Launches
T·Time Health launched cash-pay compounded injectable semaglutide and tirzepatide through its telehealth brand, ttime.men. The company says it publishes one rate regardless of the prescribed dose; the article provides no price or uptake figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Tesla’s ‘Full Self-Driving’ Becomes ‘Assisted Driving’ in Europe
- This exchange stock is a buy on renewed options deal, Morgan Stanley says
- Cramer: Investors selling Apple on latest iPhone 18 report are 'stupid as plywood'
- Teva wins FDA approval for monthly schizophrenia injection Weltruza
- BofA downgrades Alignment Healthcare stock rating on star rating drop
- Humana Stock Jumps on Raised Medicare Advantage Ratings
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Augmented Intelligence: AllMind, Elevate Human Judgement With an Accessible, Powerful, Data-Driven Financial AI Toolkit
- AI Research Systems for Hedge Funds: A Pilot Design